Optimal Empiric Polymyxin B Treatment of Patients Infected with Gram-Negative Organisms Detected Using a Blood Antimicrobial Surveillance Network in China

References

• FerriM, RanucciE, RomagnoliP, GiacconeV. Antimicrobial resistance: a global emerging threat to public health systems. Crit Rev Food Sci Nutr. 2017;57(13):2857–2876. doi:10.1080/10408398.2015.107719226464037
   PubMed Web of Science ®Google Scholar
• XuL, SunX, MaX. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017;16(1):18. doi:10.1186/s12941-017-0191-328356109
   PubMed Web of Science ®Google Scholar
• GiannellaM, TrecarichiEM, De RosaFG, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study. Clin Microbiol Infect. 2014;20(12):1357–1362. doi:10.1111/1469-0691.1274724980276
   PubMed Web of Science ®Google Scholar
• HuFP, GuoY, ZhuDM, et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005–2014. Chin J Infect Chemother. 2017;17(1):93–99.
   Web of Science ®Google Scholar
• HuF, GuoY, ZhuD. CHINET surveillance of bacterial resistance across tertiary hospitals in 2019. Chin J Infect Chemother. 2020;20(03):6–16.
   Google Scholar
• YangY, GuoY, YinD, et al. In vitro activity of cefepime-zidebactam, ceftazidime-avibactam, and other comparators against clinical isolates of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii: results from China Antimicrobial Surveillance Network (CHINET) in 2018. Antimicrob Agents Chemother. 2020;65:1. doi:10.1128/AAC.01726-20
   Web of Science ®Google Scholar
• Koch-WeserJ, SidelVW, FedermanEB, KanarekP, FinerDC, EatonAE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med. 1970;72(6):857–868. doi:10.7326/0003-4819-72-6-8575448745
   PubMedGoogle Scholar
• StormDR, RosenthalKS, SwansonPE. Polymyxin and related peptide antibiotics. Annu Rev Biochem. 1977;46:723–763. doi:10.1146/annurev.bi.46.070177.003451197881
   PubMed Web of Science ®Google Scholar
• NationRL, VelkovT, LiJ. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis. 2014;59(1):88–94. doi:10.1093/cid/ciu21324700659
   PubMed Web of Science ®Google Scholar
• HuangChen, XiaoYonghong. Polymyxins: review on clinical use and dilemma. Her Med. 2020;39(1):10–16.
   Google Scholar
• GaronzikSM, LiJ, ThamlikitkulV, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically Ill patients from a Multicenter Study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55(7):3284–3294. doi:10.1128/AAC.01733-1021555763
   PubMed Web of Science ®Google Scholar
• SandriAM, LandersdorferCB, JacobJ, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis. 2013;57(4):524–531. doi:10.1093/cid/cit33423697744
   PubMed Web of Science ®Google Scholar
• KassamaliZ, DanzigerL. To B or not to B, that is the question: is it time to replace colistin with polymyxin B? Pharmacotherapy. 2015;35(1):17–21. doi:10.1002/phar.151025346395
   PubMed Web of Science ®Google Scholar
• PheK, LeeY, McDaneldPM, et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother. 2014;58(5):2740–2746. doi:10.1128/AAC.02476-1324566187
   PubMed Web of Science ®Google Scholar
• AkajagborDS, WilsonSL, Shere-WolfeKD, DakumP, CharuratME, GilliamBL. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis. 2013;57(9):1300–1303. doi:10.1093/cid/cit45323840000
   PubMed Web of Science ®Google Scholar
• WattalC, OberoiJK, GoelN, RaveendranR, KhannaS. Matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) for rapid identification of micro-organisms in the routine clinical microbiology laboratory. Eur J Clin Microbiol. 2017;36(5):807–812. doi:10.1007/s10096-016-2864-9
   Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. Available from: http://www.clsi.org/. Accessed 121, 2020.
   Google Scholar
• WangP, ZhangQ, ZhuZ, et al. Comparing population pharmacokinetics and acute kidney injury of polymyxin B in Chinese patients with and without renal insufficiency. Antimicrob Agents Chemother. 2021;65(2):e01900–20.33168613
   PubMed Web of Science ®Google Scholar
• CheahSE, WangJ, NguyenVT, TurnidgeJD, LiJ, NationRL. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. J Antimicrob Chemother. 2015;70(12):3291–3297. doi:10.1093/jac/dkv26726318190
   PubMed Web of Science ®Google Scholar
• Xellia Pharmaceuticals APS (2016) Polymyxin B sulfate injection [package Insert]. 16 February 2016. Xellia Pharmaceuticals APS, Denmark.
   Google Scholar
• DudhaniRV, TurnidgeJD, NationRL, LiJ. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother. 2010;65(9):1984–1990. doi:10.1093/jac/dkq22620573659
   PubMed Web of Science ®Google Scholar
• MiglisC, RhodesNJ, AvedissianSN, et al. Population pharmacokinetics of polymyxin B in acutely ill adult patients. Antimicrob Agents Chemother. 2018;62(3):3. doi:10.1128/AAC.01475-17
   Web of Science ®Google Scholar
• LiJ, CoulthardK, NationRL. Labelling conventions and product package insert of parenteral polymyxins: factors causing potential medication errors and impeding optimal clinical use. Adv Exp Med Biol. 2019;1145:133–141.31364076
   PubMed Web of Science ®Google Scholar
• TsujiBT, PogueJM, ZavasckiAP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10–39. doi:10.1002/phar.220930710469
   PubMed Web of Science ®Google Scholar
• BradleyJS, DudleyMN, DrusanoGL. Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J. 2003;22(11):982–992. doi:10.1097/01.inf.0000094940.81959.1414614372
   PubMed Web of Science ®Google Scholar
• De RosaFG, PaganiN, FossatiL, et al. The effect of inappropriate therapy on bacteremia by ESBL-producing bacteria. Infection. 2011;39(6):555–561. doi:10.1007/s15010-011-0201-x22048926
   PubMed Web of Science ®Google Scholar
• MicekS, JohnsonMT, ReichleyR, KollefMH. An institutional perspective on the impact of recent antibiotic exposure on length of stay and hospital costs for patients with gram-negative sepsis. BMC Infect Dis. 2012;12(1):56. doi:10.1186/1471-2334-12-5622414209
   PubMed Web of Science ®Google Scholar
• WangQ, WangZ, ZhangF, et al. Long-term continuous antimicrobial resistance surveillance among nosocomial gram-negative bacilli in China from 2010 to 2018 (CMSS). Infect Drug Resist. 2020;13:2617–2629. doi:10.2147/IDR.S25310432801799
   PubMed Web of Science ®Google Scholar
• WangC, HaoW, JinY, ShenC, WangB. Pharmacokinetic/pharmacodynamic modeling of seven antimicrobials for empiric treatment of adult bloodstream infections with gram-negative bacteria in China. Microb Drug Resist. 2020;26(12):1559–1567. doi:10.1089/mdr.2019.015231794682
   PubMed Web of Science ®Google Scholar
• YuX-B, JiaoZ, ZhangC-H, et al. Population pharmacokinetic and optimization of polymyxin B dosing in adult patients with various renal functions. Br J Clin Pharmacol. 2021;87(4):1869–1877. doi:10.1111/bcp.1457633002196
   PubMed Web of Science ®Google Scholar
• ManchandaniP, ThamlikitkulV, DubrovskayaY, et al. Population pharmacokinetics of polymyxin B. Clin Pharmacol Ther. 2018;104(3):534–538. doi:10.1002/cpt.98129238962
   PubMed Web of Science ®Google Scholar
• KubinCJ, EllmanTM, PhadkeV, HaynesLJ, CalfeeDP, YinMT. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect. 2012;65(1):80–87. doi:10.1016/j.jinf.2012.01.01522326553
   PubMed Web of Science ®Google Scholar
• RigattoMH, BehleTF, FalciDR, et al. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. J Antimicrob Chemother. 2015;70(5):1552–1557. doi:10.1093/jac/dku56125604744
   PubMed Web of Science ®Google Scholar
• LakotaEA, LandersdorferCB, NationRL, et al. Personalizing polymyxin B dosing using an adaptive feedback control algorithm. Antimicrob Agents Chemother. 2018;62(7). doi:10.1128/AAC.00483-18
   Web of Science ®Google Scholar
• Garnacho-MonteroJ, Ortiz-LeybaC, Jimenez-JimenezFJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis. 2003;36(9):1111–1118. doi:10.1086/37433712715304
   PubMed Web of Science ®Google Scholar
• KallelH, HergafiL, BahloulM, et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med. 2007;33(7):1162–1167. doi:10.1007/s00134-007-0675-217530220
   PubMed Web of Science ®Google Scholar
• PoudyalA, HowdenBP, BellJM, et al. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother. 2008;62(6):1311–1318. doi:10.1093/jac/dkn42518922815
   PubMed Web of Science ®Google Scholar
• Lopez-RojasR, McConnellMJ, Jimenez-MejiasME, Dominguez-HerreraJ, Fernandez-CuencaF, PachonJ. Colistin resistance in a clinical Acinetobacter baumannii strain appearing after colistin treatment: effect on virulence and bacterial fitness. Antimicrob Agents Chemother. 2013;57(9):4587–4589. doi:10.1128/AAC.00543-1323836165
   PubMed Web of Science ®Google Scholar
• BeyrouthyR, RobinF, LesseneA, et al. MCR-1 and OXA-48 in vivo acquisition in KPC-producing Escherichia coli after colistin treatment. Antimicrob Agents Chemother. 2017;61(8). doi:10.1128/AAC.02540-16
   Web of Science ®Google Scholar